The Wolverine stack is BPC-157 and TB-500 in one vial, usually 10 mg of each. MuscleLedger's Wolverine stack page counts what exists in humans for each compound and separates healing from muscle growth. This page is narrower: it is the dose record, and this month it changed.
It reports what sources state and recommends nothing.
Both halves are now in the registry
Until this year neither compound had a registered human study of its own. There are now three, and the first two were filed by the same sponsor.
| Registration | Compound | Design | Status | Dose stated |
|---|---|---|---|---|
| NCT07437547 | BPC-157 | Phase 2, placebo-controlled, acute hamstring strain, 120 planned | Recruiting since 2 Feb 2026, China | None — "subcutaneous injection… once daily for 14 days" |
| NCT07487363 | TB-500 | Phase 1/2, randomized, double-blind, sequential dose escalation, stable cardiovascular disease, 80 planned | Recruiting since 5 Feb 2026, Peking University Shenzhen Hospital | None — arms named "Low Dose", "Medium Dose", "High Dose" |
| NCT07803250 | BPC-157 | Phase 1, after rotator cuff repair, 30 planned | Not yet recruiting, planned start 1 Jan 2027, University of Arkansas | None — "once daily for 90 days" |
The sponsor of the first two is Hudson Biotech, the filer this site's MOTS-c dosage page examined in September: eight registrations from one sponsor inside a two-week window, covering MOTS-c, BPC-157, TB-500, GHK-Cu, Melanotan II, tesamorelin, tirzepatide and retatrutide, two of them carrying Eli Lilly's own protocol identifiers. Both records read here carry isFdaRegulatedDrug: false.
The finding for anyone hoping a registration would settle the dose question: none of the three publishes a milligram amount. A dose-escalation study with three unlabelled dose arms is the clearest case — the study exists to find a dose and has not said what it is testing.
One more detail belongs on the record. The Arkansas filing describes its control arm twice and the two descriptions disagree: the arm group says normal saline, self-administered subcutaneously once daily for 90 days, while the intervention entry for that arm says participants "will not receive any active treatment or placebo injections". A sham-injection control and a no-treatment control answer different questions.
The published dose figures, such as they are
| Figure | Compound | Route | Source | Kind |
|---|---|---|---|---|
| 4 mg, single dose | BPC-157 | Intra-articular (knee) | Retrospective series, 12 patients, reviewed in HSS Journal 2025 | Published, uncontrolled |
| 6 mcg/kg – 20 mg/kg | BPC-157 | IM, IV, IP, oral | Animal studies in the same review | Preclinical, spans 3 orders of magnitude |
| 250–500 mcg/day | BPC-157 | Subcutaneous | Clinic and vendor pages, 2025–2026 | Convention |
| 2–2.5 mg twice weekly | TB-500 | Subcutaneous | Community protocol pages | Convention |
| 42–1,260 mg / 0.05–25 mcg/kg | Thymosin beta-4 (not TB-500) | Intravenous | Phase 1 trials in healthy volunteers, 2010 and 2022 | Published, different molecule |
The full records behind these sit on our BPC-157 dosage page and TB-500 dosage page. The last row is the trap: the protein's trial doses are four orders of magnitude apart from the fragment's convention, and they are not doses of the same substance.
The frequency problem a premixed vial creates
At 10 mg and 10 mg, the vial is 1:1. Every draw contains equal amounts of both peptides. The two conventions attached to those peptides, however, are not on the same clock.
| Following… | BPC-157 per week | TB-500 per week |
|---|---|---|
| BPC-157's daily convention (250–500 mcg/day) | 1.75–3.5 mg | 1.75–3.5 mg (its convention: 4–5 mg while loading) |
| TB-500's twice-weekly convention (2–2.5 mg × 2) | 4–5 mg, all on two days | 4–5 mg |
Neither column satisfies both conventions. The daily pattern delivers TB-500 at roughly 35% to 90% of its own loading figure; the twice-weekly pattern delivers BPC-157 at 1.1 to 2.9 times its weekly figure and nothing on five days of the week. This is arithmetic from the labels, not a recommendation, and it is the practical reason the premixed form and the per-compound conventions cannot both be right.
Sellers who mix the pair at other ratios move the problem rather than solving it; the four-peptide KLOW blend shows the same effect at 5:1:1:1.
What is not established
- No dose for the combination from any regulator, trial or registry.
- No published amount in any of the three registrations of the components.
- No human study of TB-500 with a published result — its one registration is recruiting.
- No controlled human study of BPC-157 at any dose; the single human report is retrospective and uncontrolled.
- No published pharmacokinetics for either compound in people, so no figure can be converted between routes.
What a reader can check in five minutes
- Open NCT07487363 and look for a milligram figure in the arm labels.
- Open NCT07437547 and read the intervention description in full.
- Open NCT07803250 and compare its arm-group text with its intervention text.
- Search the registry for BPC-157 with TB-500 as a combination.
- Check whether any page quoting a stack dose says which vial ratio it assumes.
Related on this site
Peptide stacks explained holds the registry census for every named blend and the reason component evidence cannot support a combination claim. KLOW dosage covers the four-peptide version of the same product category. The peptide dosage chart indexes all of this site's dose records by the kind of source behind each figure.
Sources and dates
Opened 17 September 2026: the ClinicalTrials.gov v2 API records for NCT07437547, NCT07487363 and NCT07803250 in full, including arm groups, interventions, sponsors, oversight fields and locations; and the registry census on this site's peptide stacks page dated 16 September 2026. Dose conventions and the HSS Journal figures are carried from this site's sourced BPC-157 and TB-500 pages, opened 5 September 2026. Corrections go to the contact page.